Cylene Pharmaceuticals

Cylene Pharmaceuticals Calls on TetraGene to Advance Anti-Cancer Technologies

The agreement is aimed to advance the ocmpany’s quadruplex-targeting technologies.

Cylene Pharmaceuticals, Inc. announced today that it has entered into an exclusive, worldwide Option and License Agreement that will allow TetraGene LLC to advance the development of Quarfloxin and Cylene's associated anticancer quadruplex-targeting technologies. Cylene will receive an upfront fee, as well as potential milestone payments and royalties on product sales for the exclusive license. 

No votes yet
Syndicate content